Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Dec;7(24):797.
doi: 10.21037/atm.2019.12.65.

Increased m6A methylation level is associated with the progression of human abdominal aortic aneurysm

Yuchen He  1 , Jia Xing  2 , Shiyue Wang  1 , Shijie Xin  1 , Yanshuo Han  3   4 , Jian Zhang  1
Affiliations

Increased m6A methylation level is associated with the progression of human abdominal aortic aneurysm

Yuchen He et al. Ann Transl Med. 2019 Dec.

Abstract

Background: The role of N6-methyladenosine (m6A) modification in abdominal aortic aneurysm (AAA) has not been extensively studied. This study therefore aimed to investigate m6A RNA methylation and the expressions of the corresponding modulators in AAA.

Methods: A comparative study between AAA tissue samples (n=32) and healthy aortas (n=12) was performed using m6A methylation quantification for messenger RNA (mRNA) m6A status, quantitative polymerase chain reaction (qPCR), and western blot for the expressions of m6A modulators and immunohistochemistry (IHC) to detect locations of the modulators in AAA tissues.

Results: The m6A level significantly increased in AAA as compared to healthy aorta tissues. Among AAA patients, the high m6A level represented an even greater risk of AAA rupture as compared to non-ruptured AAA [odds ratio (OR), 1.370; 95% confidence interval (CI), 1.007-1.870]. The major N6-adenosine modulators, including YTHDF1, YTHDF3, FTO, and METTL14, are the main factors involved in aberrant m6A modification and the expression of both was significantly correlated to the proportion of m6A in total mRNA. Clinically, YTHDF3 represented an even greater risk of rupture (OR, 1.036; 95% CI, 1.001-1.072). Regarding the cellular location, METTL14 seemed to be associated with inflammatory infiltrates and neovascularization. Furthermore, a strong correlation was seen between FTO and aneurysmal smooth muscle cells (SMCs), YTHDF3, and macrophage infiltrate.

Conclusions: We were first to observe m6A modification in human AAA tissues. The results also reveal the important roles of m6A modulators, including YTHDF3, FTO, and METTL14, in the pathogenesis of human AAA and provide a new view on m6A modification in AAA. Our findings suggest a potential mechanism of epigenetic alterations in clinical AAA.

Keywords: Abdominal aortic aneurysm (AAA); N6-methyladenosine RNA methyltransferase (m6A RNA methyltransferase); N6-methyladenosine modification (m6A modification); epigenetics.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Flowchart of AAA patient selection and biopsy tissue or blood sample recovered from CMU-aB. AAA, abdominal aortic aneurysm; FFPE, formalin-fixed paraffin-embedded; CMU-aB, China Medical University Aneurysm Biobank.
Figure 2
Figure 2
Expression of m6A RNA methylation status (A) and m6A methylation modulators (B,C,D,E,F,G,H) at the mRNA level in AAA tissue samples compared with the healthy control aortas, analyzed by qRT-PCR and SYBR Master Mix. The non-parametric Mann-Whitney U test was applied to analyze the mRNA methylation status (A); the m6A “writers” family, METTL3 (B) and METTL14 (C); m6A “erasers” family, ALBH5 (D) and FTO (E); and “readers” family, YTHDF 1 (F), YTHDF2 (G), and YTHDF3 (H). Dates are normalized to the expression of GAPDH and analyzed through the non-parametric Mann-Whitney U test. *, P<0.05; **, P<0.01. m6A, N6-methyladenosine; AAA, abdominal aortic aneurysm; qRT-PCR, quantitative real-time polymerase chain reaction; ns, not significant.
Figure 3
Figure 3
Expression analysis of METTL14 (A), FTO (B), YTHDF1 (C), and YTHDF3 (D) in AAA and healthy aortas at the protein level through the non-parametric Mann-Whitney U test. At top are the raw images of blots by Western blot, and at bottom is quantification of the band intensities relative to the expression of GAPDH. ***, P<0.001. C and Ctrl, control healthy aorta (n=12); A and AAA, specimens of abdominal aortic aneurysm (n=32).
Figure 4
Figure 4
Analysis of METTL14 (A), FTO (B), and YTHDF3 (C) in AAA using IHC for cellular localization. Overview image (left panel) of the whole AAA tissue sample with areas selected for cellular localization of m6A modulator expressions (HE staining). The magnified images depict consecutive staining of individual cell types, as revealed by staining for indicated markers within the AAA wall and indicated corresponding substrates. Scale bar, 50 µm. AAA, abdominal aortic aneurysm; IHC, immunohistochemistry; m6A, N6-methyladenosine; HE, hematoxylin-eosin; SMC, smooth muscle cell; EC, endothelial cell.
Figure 5
Figure 5
Analysis of acetylated METTL14 (A), FTO (C), and YTHDF3 (E) in AAA using IHC, compared with their expressions in healthy control aortic tissues (B,D,F). Scale bar, 50 µm. AAA, abdominal aortic aneurysm; IHC, immunohistochemistry.
Figure S1
Figure S1
AAA is a frequent vascular disorder with high mortality and accumulation of several cell types, including leukocytes, lymphocytes, macrophages, endothelial, and smooth muscle cells. Alternations in m6A modification were clearly observed in AAA compared to healthy aortas. Furthermore, m6A modification in AAA was also correlated with clinical data and associated with a higher risk of AAA rupture. m6A, N6-methyladenosine; AAA, abdominal aortic aneurysm; VSMC, vascular smooth muscle cell.
See this image and copyright information in PMC

References

    1. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006;113:e463-654. - PubMed
    1. Sakalihasan N, Limet R, Defawe OD. Abdominal aortic aneurysm. Lancet 2005;365:1577-89. 10.1016/S0140-6736(05)66459-8 - DOI - PubMed
    1. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J 2014;35:2873-926. 10.1093/eurheartj/ehu281 - DOI - PubMed
    1. Han YS, Zhang J, Xia Q, et al. A comparative study on the medium-long term results of endovascular repair and open surgical repair in the management of ruptured abdominal aortic aneurysms. Chin Med J (Engl) 2013;126:4771-9. - PubMed
    1. Yin M, Zhang J, Wang Y, et al. Deficient CD4+CD25+ T regulatory cell function in patients with abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2010;30:1825-31. 10.1161/ATVBAHA.109.200303 - DOI - PubMed

LinkOut - more resources